- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02963597
Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea. (ASAP-HF)
Auto-PAP for Pulmonary Hypertension Treatment in Decompensated Heart Failure Patients With Obstructive Sleep Apnea: A Two Center Pilot Study
Study Overview
Status
Intervention / Treatment
Detailed Description
The ASAP-HF study is a prospective, randomized, controlled, two-center, study with a parallel group design, with subjects randomized to either control (no APAP) or active treatment (APAP) in a 1:1 ratio. Group A (active): standard medical therapy plus treatment with continuous APAP for 48hrs, or Group B (control): standard medical therapy only.
Many people who have heart failure (HF) also have sleep-disordered breathing (SDB), which is breathing irregularities during sleep. These irregularities may interrupt the sleep as well as increase the rate of progression of Heart Failure. The ASAP-HF study is being done to see if certain clinical outcomes are improved in acute decompensated heart failure (HF) patients with SDB by using a non-invasive breathing device continuously for a short period of time (48 hours) while patient is still in the hospital. The device is called AirSense™ 10 AutoSet (AutoSet). It consists of an air flow generator, air tubing, an air humidifier, and a mask. As the patient breathe through the mask, the AutoSet monitors breathing.
The primary objective of this pilot study is to evaluate the effect of continuous positive airway pressure (PAP) therapy on pulmonary arterial (PA) pressures in acute decompensated heart failure (HF) patients with obstructive sleep apnea (OSA). The study will also assess changes in functional parameters, biomarkers, and echocardiographic parameters . This device is not currently used to diagnose sleep apnea and its utility is not well studied. This study will establish the utility of the device in diagnosing sleep apnea.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Rhine-Westphalia
-
Bad Oeynhausen, North Rhine-Westphalia, Germany, 32545
- Heart and Diabetes Center NRW
-
-
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19141
- Albert Einstein Healthcare Network
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or more
- Decompensated Congestive Heart Failure with systolic Pulmonary Artery pressures of ≥50 mmHg (including Right Atrial pressure)
- Prior clinical diagnosis of heart failure
- Moderate to Severe predominately obstructive sleep disordered breathing documented by polygraphy with Apnea Hypopnea Index (AHI) ≥20e/h and 5% of the time spent <90% O2 Sat (minimum 2hr recording time)
- Patient is able to fully understand study information and sign informed consent
Exclusion Criteria:
- Chronic renal insufficiency (Hemodialysis or serum creatinine > 2)
- Hemodynamically significant valvular disease
- Severe arthritis or inability to complete 6 Minute Walk Test
- Left Ventricular Assist Device/ heart transplant or hemodynamically unstable
- Patient taking any Pulmonary vasodilators, including home oxygen.
- Known diagnosis of Obstructive Sleep Apnea (OSA) and on active therapy
- 80% of the respiratory events being central/Cheyne-Stokes breathing
- Recent cardiac surgery (within 30 days of admission)
- Recent stroke (within 30 days of admission or with persistent neurological deficits)
- Severe Chronic Obstructive Pulmonary Disease defined as forced expiratory volume at one second (FEV1) < 50%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A
Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
|
The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing.
The device is intended for home and hospital use.
The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance.
In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency.
The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard medical therapy according to current guidelines.
|
Placebo Comparator: Group B
Standard medical therapy only.
|
Standard medical therapy according to current guidelines.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulmonary Artery Systolic Pressure.
Time Frame: 48 hours
|
The primary objective of this pilot study is to evaluate the effect of continuous positive airway pressure (PAP) therapy on pulmonary arterial (PA) pressures in acute decompensated heart failure (HF) patients with severe obstructive sleep apnea (OSA).
The study will also assess changes in functional parameters, biomarkers, and echocardiographic parameters.
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Parameters (6 Minute Walk Test) From Baseline to 48hrs
Time Frame: 48 hours
|
6-minute walk tests were performed on admission and repeated after 48 hours from the initial.
The walked distance was measured in meters.
|
48 hours
|
N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline to 48hrs
Time Frame: 48 hours
|
To compare changes in N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) measured at baseline and compared to 48hrs after.
|
48 hours
|
Length of Stay
Time Frame: 1 year
|
The total stay in the hospital during the admission will be measured by days.
|
1 year
|
Blood Oxygenation.
Time Frame: 48 hours
|
Changes in arterial blood oxygenation will be compared via arterial blood gas analysis performed at baseline and after 48h to assess arterial pressure of oxygen.
|
48 hours
|
Heart Failure Symptoms
Time Frame: 48 hours
|
Heart failure symptoms as assessed by the New York Heart Association scale (NYHA) classification at baseline and after 48 hours. NYHA scale ranges from Class I to IV. Higher classes are associated with worst outcomes. Class I: No symptoms and no limitation in ordinary physical activity. Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: Marked limitation in activity due to symptoms, even during less-than-ordinary activity.Comfortable only at rest. Class IV: Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. |
48 hours
|
Fluid Retention
Time Frame: 48 hours
|
Change in fluid retention as measured by weight at baseline and after 48 hours.
|
48 hours
|
E/e' as an Assumption of LVEDP.
Time Frame: 48 hours
|
Measurement of E/e' in 2D echocardiography as an assumption of LVEDP and PV acceleration time comparing baseline and after 48hrs.
|
48 hours
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sunil Sharma, MD, Albert Einstein Healthcare Network
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Lung Diseases
- Signs and Symptoms, Respiratory
- Heart Failure
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Hypertension
- Apnea
- Hypertension, Pulmonary
Other Study ID Numbers
- 4889
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Duke University; St. Paul's Hospital... and other collaboratorsActive, not recruitingHeart Diseases | Heart Failure | Transplant; Failure, Heart | Heart Transplant Failure and Rejection | Heart Failure,Congestive | Transplant FailureCanada, United States
Clinical Trials on AirSense™ 10 AutoSet
-
Neurologisches Rehabiliationszentrum RosenhügelCompleted
-
Merck Sharp & Dohme LLCCompletedBacterial Infections; Virus Diseases
-
ResMedCompleted
-
Cymra Life SciencesCompletedPain | Back Pain | Chronic Pain | Neck Pain | Pain, Chronic | CBD | Pain, Back | Pain, Neck | THCAustralia
-
Pnn Medical A/SCompletedBenign Prostatic HyperplasiaDenmark
-
Göteborg UniversityEisai Inc.CompletedObesity | Obstructive Sleep Apnea | Sleep ApneaSweden
-
GlaxoSmithKlineCompletedHepatitis BBelgium, Ukraine, Australia
-
Children's Hospital Los AngelesCompleted